8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-2-phenyl-propanoateIdentifiersCAS number 60205-81-4ATC code R01AX03 R03BB01PubChem 43232DrugBank APRD00537Chemical dataFormula C20H30NO3Mol. mass 389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability atrovent child dose ?Protein binding 0 to 9% 0.

searchIpratropiumSystematic (IUPAC) name[8-methyl-8-(1-methylethyl)- atrovent child dose oct-3-yl] 3-hydroxy-2-phenyl-propanoateIdentifiersCAS number 60205-81-4ATC code R01AX03 R03BB01PubChem 43232DrugBank APRD00537Chemical dataFormula C20H30NO3Mol. mass 389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability ?Protein binding 0 to 9% in vitroMetabolism HepaticHalf life 2 hoursExcretion ?Therapeutic considerationsPregnancy cat. B(US)Legal status POM(UK)Routes InhalationIpratropium (as ipratropium bromide, atrovent child dose name Atrovent) is an anticholinergic drug administered by inhalation atrovent child dose the treatment of obstructive lung atrovent child dose It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a quaternary atrovent child dose and therefore does not diffuse into the blood, which prevents systemic side effects. Ipratropium is also atrovent child dose with albuterol (salbutamol) (trade names Combivent and Duoneb) for the treatment of obstructive lung diseases. obstructive.

HepaticHalf life 2 hoursExcretion ?Therapeutic considerationsPregnancy cat. B(US)Legal status POM(UK)Routes.